Fortress Biotech vs Recursion Pharmaceuticals
Recursion Pharmaceuticals is the larger business, with $74.7m of revenue in fiscal 2025 against $63.3m for Fortress Biotech (1.2 times as much). Recursion Pharmaceuticals grew faster (26.9% against 9.7%). Fortress Biotech kept more of each dollar of sales as profit: a net margin of 10.8% against -863.4%.
| Latest fiscal year | Fortress BiotechFBIO, 2025 | Recursion PharmaceuticalsRXRX, 2025 |
|---|---|---|
| Revenue | $63.3m | $74.7m |
| Revenue growth | 9.7% | 26.9% |
| Net income | $6.8m | −$645m |
| Operating margin | — | -867.9% |
| Net margin | 10.8% | -863.4% |
| Return on equity | 18.8% | -59.5% |
| Free cash flow | −$65.8m | −$378m |
| Cash | $79.4m | $743m |
| Total debt | $54.5m | $18.7m |
| Debt to equity | — | 1.6% |
| Dividend per share | — | — |
| Dividend yield | 0.8% | — |
| Share buybacks | — | — |
| Employees | 78 | — |
| Market value | $64.5m | $2.10bn |
| Price vs our value range | — | — |
| Moat score | 20 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 35 sales |